Integra Biosciences, a provider of high-quality laboratory tools for liquid handling, media preparation, sterilization and cell cultivation, completed the acquisition of Miroculus, a California biotech company focused on developing automation solutions that streamline next generation sequencing protocols. Financial terms were not disclosed. “The global NGS market has been growing exponentially in recent years, and seems set to continue doing so. We have acquired this promising start-up because we recognize the huge potential of its revolutionary digital microfluidics technology for automating and miniaturizing genomic protocols. Miroculus' proprietary platform delivers assay flexibility and automation capacity, which enables seamless workflow integration. This will help to remove process bottlenecks and advance science one of INTEGRA’s primary goals," Urs Hartmann, Integra CEO.